Metastatic Castration-Sensitive Prostate Cancer

Orgovyx (Myovant Sciences)

Orgovyx (relugolix) is a small molecule, gonadotropin-releasing hormone (GnRH) receptor antagonist, and an oral investigational drug candidate for the treatment of advanced prostate cancer. As a GnRH receptor antagonist, relugolix binds to and blocks the GnRH receptor (GnRHR) in the anterior pituitary gland. Blocking GnRH receptors decreases the release of gonadotropins – luteinizing hormone (LH) and follicle-stimulating hormone (FSH) – thereby decreasing the downstream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. 

Myovant is developing relugolix 120 mg following a single 360 mg loading dose as a monotherapy, investigating whether this monotherapy decreases testosterone to low levels. Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries) to relugolix. In December 2020 the company announced that the FDA approved relugolix for the treatment of adults with advanced prostate cancer. EC decision on the advanced prostate cancer MAA is expected in calendar year 2022.

Learn for more info @ Metastatic Castration-Sensitive Prostate Cancer Market Share

mCSPC Emerging Drugs

Drug chapter segment of the mCSPC report encloses the detailed analysis of mCSPC marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the mCSPC clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. 

Talazoparib (Pfizer)

Talazoparib is an inhibitor of PARP enzymes, which play a role in DNA response. Preclinical studies have demonstrated that talazoparib blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. 

Talazoparib is being evaluated in several ongoing clinical trials in prostate cancer, as well as other novel combinations with targeted therapies in various solid tumors. With the introduction of PARP inhibitors in the mCRPC setting, it is important to explore how a combination approach may impact outcomes for men with the metastatic castration-sensitive disease. 

The company also anticipated that the prognosis for men with advanced prostate cancer has significantly improved since the introduction of novel hormone therapies, but additional therapeutic options are needed for the approximately 25 percent of men with tumors harboring DNA damage response (DDR) gene mutations, who may have poorer outcomes. Combining enzalutamide – which has a proven clinical benefit in men with mCSPC – with talazoparib – active in DDR-mutated cancer – may offer a new treatment that targets the underlying genetic mechanisms associated with DDR-mutated mCSPC. 

Read for more info @ Metastatic Castration-Sensitive Prostate Cancer market forecast